Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 10/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173262 | 1.00 | CARM1 (0.50) | CARM1PRMT6IDO1AGXTMAOB | |
| SCHEMBL31173517 | 0.91 | CARM1 (0.55) | CARM1PRMT6IDO1AGXTMAOB | |
| SCHEMBL19212300 | 0.91 | CARM1 (0.55) | CARM1PRMT6IDO1AGXTMAOB | |
| SCHEMBL28444263 | 0.85 | CARM1 (0.36) | CARM1PRMT6AGXT | |
| SCHEMBL22779206 | 0.85 | CARM1 (0.36) | CARM1PRMT6AGXT | |
| SCHEMBL21266517 | 0.84 | ENPP2 (0.40) | TAAR1 | |
| SCHEMBL28445371 | 0.84 | ENPP2 (0.40) | TAAR1 | |
| SCHEMBL22305511 | 0.82 | SLC6A2 (0.35) | CARM1PRMT6AGXT | |
| SCHEMBL11244939 | 0.81 | CTSL (0.46) | CARM1PRMT6 | |
| SCHEMBL28072324 | 0.81 | CTSL (0.46) | CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CARM1 465/4885PRMT6 1239/4885IDO1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.